[Current aspects of D-penicillamine and pregnancy]. / Aktuelles zu D-Penicillamin und Schwangerschaft.
Z Rheumatol
; 47 Suppl 1: 20-3, 1988.
Article
in De
| MEDLINE
| ID: mdl-3063004
ABSTRACT
Although the outcome of most pregnancies is normal under D-penicillamine a teratogenic effect of the drug is known from animal studies. A few cases of children with birth defects whose mothers received D-penicillamine during pregnancy are reported in the literature. Whether D-penicillamine therapy should be performed throughout pregnancy or whether it should be interrupted depends on the disease to be treated. While in patients with morbus Wilson, continuous treatment with D-penicillamine is justified, it is advisable to interrupt the therapy during pregnancy in patients with rheumatoid arthritis.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Penicillamine
/
Pregnancy Complications
/
Arthritis, Rheumatoid
/
Cystinuria
/
Hepatolenticular Degeneration
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Newborn
/
Pregnancy
Language:
De
Journal:
Z Rheumatol
Year:
1988
Document type:
Article